Jul 1, 2026 · 32m · tbpn
Rocket Lab Enters SpaceX Arena, Meta’s Prediction Market, America’s Tech Wishlist | Diet TBPN
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
Hosts John Coogan and Jordi Hays break down major business and tech developments, including Rocket Lab's acquisition of Iridium to rival SpaceX, Blue Origin's launch strategy pivot, Comcast's media spin-off, prediction markets, and the rise of AI-driven solo entrepreneurship.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. The hosts hold 89.2% of the talking time here. How this is scored →
speaking balance: gold is the hosts, purple is the guest (3 minute bins)
Jordi pushes back against John's dismissal of Meta's prediction market ambitions, insisting that prediction markets routinely act as underlying infrastructure for third-party platforms.
Hardest push from the hosts ▶ 13:51 John dismantles the Meta direct competitor partnership theoryJohn rejects Jordi's interpretation of reporting on Meta, arguing that competitor partnerships are data-licensing or ad relationships rather than direct customer-sharing betting integrations.
Biggest teaching moment ▶ 11:25 IRC Section 61 and economic substance doctrine breakdownJohn reads out a direct tax law breakdown of IRC Section 61, clearly explaining why personal service income cannot be shielded via newly minted corporate shells.
The host holds their own ▶ 15:54 Detailed explanation of CFTC Section 1256 tax contractsJohn demonstrates specialized tax and financial knowledge by explaining CFTC regulated event contracts and the 60/40 capital gains split under Section 1256.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | The hosts as informed peer | Guest teaching | Guest disagreement | The hosts pushing back | Why |
|---|---|---|---|---|---|---|
| Rocket Lab Acquires Iridium to Challenge SpaceX Starlink | 7 | 3 | 1 | 1 | John delivers detailed market and technological context regarding Rocket Lab's acquisition of Iridium, tracking satellite constellations, spectrum rights, and valuation history. Peter Beck's recorded announcement explains the space application equation, which John contextualizes alongside SpaceX's moves. | |
| Comcast Splits Media Content from Telecom Connectivity Business | 7 | 0 | 0 | 0 | John provides an encyclopedic recap of the telecom-media rollup and spinout cycle over the past decade, referencing Verizon/AOL/Yahoo and AT&T/Time Warner. The hosts also touch on Blue Origin's updated launch pad concept of operations following Dave Limp's announcement. | |
| Brainstorming an AI Corporate Shell Scheme for Doctor Income | 6 | 2 | 2 | 2 | John pitches a satirical tax avoidance scheme using agentic AI to spawn Delaware C-corps for medical appointments. Jordi pushes back playfully by identifying it as tax fraud, after which John cites IRC Section 61 and economic substance doctrine. | |
| Prediction Markets, Capital Gains Tax Rules, and Meta Ambitions | 8 | 3 | 4 | 5 | John and Jordi engage in a substantive debate over Meta's potential prediction market integration. John rejects the framing that Meta will launch a real-money betting product with competitors and later breaks down Kalshi CFTC Section 1256 tax treatment rules in detail. | |
| Analyzing WSJ Reader Wishlists for Next-Gen Everyday Tech | 6 | 1 | 2 | 3 | The hosts analyze submissions from the Wall Street Journal innovation wishlist, debating the physics of solar-powered cars, thermal imaging for contactless cooking spatulas, and acoustic engineering. John counters impractical ideas with physics-based explanations regarding energy density and temperature gradients. | |
| Rivian Impressions, Autonomous Driving Commoditization, and Longevity Ambitions | 7 | 1 | 1 | 2 | John shares his perspective on testing Rivian's autonomous driving system, advancing the thesis that autonomous driving models are commoditizing rapidly like open-source LLMs. Jordi and John contrast basic consumer wishlist demands against ambitious biotech longevity goals. |